Physician profile
Andrew R Pogozelski
NPI 1215199898
$401,062.21
in general payments reported to CMS, 2019-2025
35 companies · $68K in 2025
The $68K reported for 2025 was more than what 95% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $40K · 2021: $44K · 2022: $48K · 2023: $48K · 2024: $44K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Travel and Lodging: $8,350 · Food and Beverage: $7,258 · Consulting Fee: $5,280 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,582.50 |
| Travel and Lodging | $8,350.29 |
| Food and Beverage | $7,257.62 |
| Consulting Fee | $5,280.00 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $166,572.78 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $83,593.51 | 2019-2025 | |
| Pfizer INC. | $74,789.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $40,587.08 | 2022-2025 | Winrevair, Verquvo, Belsomra |
| Akcea Therapeutics, INC. | $16,759.09 | 2019-2021 | |
| United Therapeutics Corporation | $14,124.86 | 2019-2025 | Remodulin, Tyvaso, Orenitram |
| E.R. Squibb & Sons, L.L.C. | $684.76 | 2019-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $608.21 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $506.48 | 2019-2025 | |
| Amgen INC. | $482.77 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $450.07 | 2019-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $408.99 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $226.30 | 2019-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $190.09 | 2022-2024 | Optimizer, Optimizer |
| Abbott Laboratories | $185.92 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $109.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.99 | 2023-2025 | Jardiance |
| Gilead Sciences, INC. | $67.33 | 2019 | |
| Kestra Medical Technology Services, INC. | $52.27 | 2024-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $52.09 | 2023 | |
| Boston Scientific Corporation | $49.41 | 2023-2024 | Watchman Access System, Watchman Flx |
| Vifor Pharma, INC. | $47.67 | 2019-2021 | |
| Cardiovascular Systems INC. | $46.47 | 2020 | |
| Liquidia Technologies, INC. | $43.78 | 2025 | Yutrepia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.49 | 2024 | Lifevest |
| Daiichi Sankyo INC. | $40.16 | 2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $38.21 | 2022-2023 | |
| Novo Nordisk INC | $34.17 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Cvrx, INC. | $33.47 | 2023 | Barostim Neo System |
| Medtronic, INC. | $31.99 | 2024 | Corevalve Evolut R |
| Chiesi USA, INC. | $24.47 | 2021 | |
| Astellas Pharma US INC | $19.51 | 2022 | |
| Bridgebio Pharma, INC. | $18.45 | 2025 | Attruby |
| Lantheus Medical Imaging, INC. | $15.99 | 2023 | Definity |
| Lundbeck LLC | $15.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pogozelski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.